The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks
Poly(ADP-ribose) polymerase (PARP) inhibitors enhance DNA topoisomerase I (topo I) poison-induced cytotoxicity and antitumor activity in vitro and in vivo, but the mechanism has not been defined. We investigated the role of PARP-1 in the response to topo I poisons using PARP-1-/- and PARP-1+/+ mouse embryonic fibroblasts and the potent PARP-1 inhibitor, AG14361 (Ki < 5 nmol/L). PARP-1-/- mouse embryonic fibroblasts were 3-fold more sensitive to topotecan than PARP-1+/+ mouse embryonic fibroblasts (GI50, 21 and 65 nmol/L, respectively). AG14361 caused a >3-fold sensitization of PARP-1+/+ cells to topotecan compared with a <1.4-fold sensitization in PARP-1-/- cells. In human leukemia K562 cells, AG14361 caused a 2-fold sensitization to camptothecin-induced cytotoxicity. AG14361 did not affect the cellular activity of topo I as determined by measurement of cleavable complexes and topo I relaxation activity, showing that sensitization was not due to topo I activation. In contrast, repair of DNA following camptothecin removal, normally very rapid, was significantly retarded by AG14361, resulting in a 62% inhibition of repair 10 minutes after camptothecin removal. This led to a 20% increase in the net accumulation of camptothecin-induced DNA strand break levels in cells coexposed to AG14361 for 16 hours. We investigated the DNA repair mechanism involved using a panel of DNA repair-deficient Chinese hamster ovary cells. AG14361 significantly potentiated camptothecin-mediated cytotoxicity in all cells, except the base excision repair-deficient EM9 cells. Therefore, the most likely mechanism for the potentiation of topo I poison-mediated cytotoxicity by AG14361 is via PARP-1-dependent base excision repair.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2005 |
---|---|
Erschienen: |
2005 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 11(2005), 23 vom: 01. Dez., Seite 8449-57 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Smith, Lisa M [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 24.01.2006 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM159258871 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM159258871 | ||
003 | DE-627 | ||
005 | 20231223083800.0 | ||
007 | tu | ||
008 | 231223s2005 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0531.xml |
035 | |a (DE-627)NLM159258871 | ||
035 | |a (NLM)16322308 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Smith, Lisa M |e verfasserin |4 aut | |
245 | 1 | 4 | |a The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks |
264 | 1 | |c 2005 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 24.01.2006 | ||
500 | |a Date Revised 19.11.2015 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Poly(ADP-ribose) polymerase (PARP) inhibitors enhance DNA topoisomerase I (topo I) poison-induced cytotoxicity and antitumor activity in vitro and in vivo, but the mechanism has not been defined. We investigated the role of PARP-1 in the response to topo I poisons using PARP-1-/- and PARP-1+/+ mouse embryonic fibroblasts and the potent PARP-1 inhibitor, AG14361 (Ki < 5 nmol/L). PARP-1-/- mouse embryonic fibroblasts were 3-fold more sensitive to topotecan than PARP-1+/+ mouse embryonic fibroblasts (GI50, 21 and 65 nmol/L, respectively). AG14361 caused a >3-fold sensitization of PARP-1+/+ cells to topotecan compared with a <1.4-fold sensitization in PARP-1-/- cells. In human leukemia K562 cells, AG14361 caused a 2-fold sensitization to camptothecin-induced cytotoxicity. AG14361 did not affect the cellular activity of topo I as determined by measurement of cleavable complexes and topo I relaxation activity, showing that sensitization was not due to topo I activation. In contrast, repair of DNA following camptothecin removal, normally very rapid, was significantly retarded by AG14361, resulting in a 62% inhibition of repair 10 minutes after camptothecin removal. This led to a 20% increase in the net accumulation of camptothecin-induced DNA strand break levels in cells coexposed to AG14361 for 16 hours. We investigated the DNA repair mechanism involved using a panel of DNA repair-deficient Chinese hamster ovary cells. AG14361 significantly potentiated camptothecin-mediated cytotoxicity in all cells, except the base excision repair-deficient EM9 cells. Therefore, the most likely mechanism for the potentiation of topo I poison-mediated cytotoxicity by AG14361 is via PARP-1-dependent base excision repair | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a 1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one |2 NLM | |
650 | 7 | |a Antineoplastic Agents, Phytogenic |2 NLM | |
650 | 7 | |a Azulenes |2 NLM | |
650 | 7 | |a Enzyme Inhibitors |2 NLM | |
650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
650 | 7 | |a Topoisomerase I Inhibitors |2 NLM | |
650 | 7 | |a Benzodiazepines |2 NLM | |
650 | 7 | |a 12794-10-4 |2 NLM | |
650 | 7 | |a Topotecan |2 NLM | |
650 | 7 | |a 7M7YKX2N15 |2 NLM | |
650 | 7 | |a DNA Topoisomerases, Type I |2 NLM | |
650 | 7 | |a EC 5.99.1.2 |2 NLM | |
650 | 7 | |a Camptothecin |2 NLM | |
650 | 7 | |a XT3Z54Z28A |2 NLM | |
700 | 1 | |a Willmore, Elaine |e verfasserin |4 aut | |
700 | 1 | |a Austin, Caroline A |e verfasserin |4 aut | |
700 | 1 | |a Curtin, Nicola J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 11(2005), 23 vom: 01. Dez., Seite 8449-57 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2005 |g number:23 |g day:01 |g month:12 |g pages:8449-57 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2005 |e 23 |b 01 |c 12 |h 8449-57 |